Daunorubicin
Back to search| Scientific Name: | Daunorubicin |
| Brand Name: | Cerubidine, Vyxeos |
| Company Owner: | Gilead sciences inc, Bedford laboratories div ben venue laboratories inc, Sanofi aventis us llc, Wyeth ayerst research, App pharmaceuticals llc, Teva parenteral medicines inc |
| Mechanism Of Action | Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. |
| Description of the Drug: | Daunorubicin is an anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia. |
| Protein Data Bank: |
|
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00694
